

Art Unit: 1624

## **DETAILED ACTION**

### **EXAMINER'S AMENDMENT**

#### ***Current Status of 10 / 516704***

1. The rejection under 35 USC 112 1<sup>st</sup> paragraph is overcome by the amendment filed 11/8/2007.
2. The rejection under 35 USC 112 2<sup>nd</sup> paragraph is overcome by the amendment filed 11/8/2007.
3. The claim objections are overcome by the amendment filed 11/8/2007.
4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Balarum Gupta on 1/29/2008.

The text in each of claims 22-28:

"central or peripheral neurodegenerative diseases; amyotrophic lateral sclerosis, multiple sclerosis; cardiovascular conditions; peripheral neuropathies; damage to the optic nerve and to the retina; spinal cord trauma and cranial trauma; atherosclerosis; stenoses; cicatrization; alopecia; cancers; tumours; metastases; leukaemias; chronic neuropathic and inflammatory pain; autoimmune diseases; or bone fractures"

has been deleted and replaced with the phrase

---pain, Parkinson's disease, prostate cancer, and atherosclerosis---

#### ***Allowable Subject Matter***

5. Claims 1-28 are allowed.
6. The following is an examiner's statement of reasons for allowance: Welch et al. (US 4994455, issued February 19, 1991) teach example 1 (columns 5-6) which fails to anticipate or render obvious compounds of formula I because variable R4 is pyrimidine and the linker

Art Unit: 1624

between the carbonyl group and the piperazine is 3 carbons instead of 2 carbons. In addition, the phenyl group is monosubstituted, not disubstituted.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Noble Jarrell whose telephone number is (571) 272-9077. The examiner can normally be reached on M-F 7:30 A.M - 6:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Noble Jarrell/  
Examiner, Art Unit 1624

/James O. Wilson/  
Supervisory Patent Examiner  
Art Unit 1624

Art Unit: 1624